Pharma News

Fulvestrant by Kashiv BioSciences for Metastatic Breast Cancer: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Fulvestrant overview

Fulvestrant is under development for the treatment of metastatic breast cancer. The drug candidate is a selective estrogen receptor degrader (SERD), acts by targeting estrogen receptor alpha and beta and is administered through parenteral route.

Kashiv BioSciences overview

Kashiv BioSciences (Kashiv) formerly known as Kashiv Pharma, is a pharmaceutical research company. It develops drug delivery platforms to create improved versions of medicines for patients and physicians. The company also develops innovative technologies, medicines, and life cycle management products. Kashiv provides services such as formulation development, analytical development and clinical supply manufacturing. It also offers contract research and development services to the pharmaceutical sector. Kashiv provides advanced deterrent technologies, formulation and controlled release technologies. The company works in partnership with pharmaceutical companies to commercialize its products. It operates a research and development facility in the US. Kashiv is headquartered in Bridgewater, New Jersey, the US.

For a complete picture of Fulvestrant’s drug-specific PTSR and LoA scores, buy the report here.


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.

Source link
#Fulvestrant #Kashiv #BioSciences #Metastatic #Breast #Cancer #Likelihood #Approval

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *